Posters

Clinical outcomes of a new non-diffractive presbyopia-correcting intraocular lens in Australia

Poster Details

First Author: F.Howes AUSTRALIA

Co Author(s):    A. Martinez   U. Bhatt   C. Balachandran              

Abstract Details

Purpose:

To evaluate the effectiveness and safety of the new non-diffractive presbyopia-correcting intraocular lens (IOL), AcrySof® IQ Vivity (model DFT015) versus an aspheric monofocal IOL (model SN60WF) in the Australian sub-population of patients of a multi-country clinical trial.

Setting:

Three investigational sites in Australia.

Methods:

This prospective, multicentre, randomised, parallel-group, assessor- and patient-masked clinical study included 63 patients from three sites in Australia; 36 and 27 patients were implanted with DFT015 and SN60WF, respectively, and 34 and 27 binocularly-implanted patients completed the Month 6 visit. Binocular best-corrected distance visual acuity (BCDVA; 4 m), distance-corrected intermediate visual acuity (DCIVA; 66 cm), and distance-corrected near visual acuity (DCNVA; 40 cm) were assessed at Month 6. Defocus curves and quality of vision (using the Quality of Vision Questionnaire) were also assessed.

Results:

Mean binocular DCIVA was improved for DFT015 (0.112 logMAR) versus SN60WF (0.301 logMAR) at Month 6, with a >1-line difference (0.189 logMAR). DCNVA was improved with DFT015 versus SN60WF (0.364 vs 0.506 logMAR), with a >1-line difference (difference of 0.142 logMAR); the between-group difference for BCDVA was <1 line (DFT015 -0.079 vs SN60WF -0.113 logMAR, difference of 0.034 logMAR). DFT015 showed a continuous extended range of vision of >0.5 D at 0.2 logMAR compared with SN60WF. For both groups, most patients were not at all bothered by starbursts, halos, and glare, with no reported severe visual disturbances in either group.

Conclusions:

In the Australian sub-population of the larger clinical study, the new non-diffractive presbyopia-correcting IOL, AcrySof® IQ Vivity DFT015 provided patients with an extended range of vision, and improved near and intermediate vision versus the aspheric monofocal IOL SN60WF, while maintaining good distance vision and a visual disturbance profile comparable to an aspheric monofocal IOL.

Financial Disclosure:

is employed by a for-profit company with an interest in the subject of the presentation, research is funded, fully or partially, by a competing company, research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, receives consulting fees, retainer, or contract payments from a competing company, receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented